Recombinant Human VEGFC Protein，His

VEGFC (Vascular Endothelial Growth Factor C) is a key protein in the VEGF family, primarily involved in lymphangiogenesis, the formation of lymphatic vessels, and angiogenesis, the formation of blood vessels. Its significance has been highlighted in numerous studies linking VEGFC to both normal physiological processes and various pathological conditions, including cancer, cardiovascular diseases, and lymphedema. In cancer, VEGFC has been implicated in promoting tumor metastasis by enhancing lymphatic vessel development, thereby facilitating the spread of cancer cells. Research on VEGFC recombinant proteins has gained momentum as it offers the potential to understand its biological functions in greater detail and develop therapeutic interventions. By producing VEGFC as a recombinant protein, researchers can investigate its structure, signaling pathways, and interactions with receptors such as VEGFR-3. Additionally, studying VEGFC in a controlled environment helps unravel its role in the vascular system and its implications in disease progression. The development of VEGFC-based therapies, encompassing either inhibition of its action to combat tumor growth or stimulation to promote wound healing and tissue regeneration, underscores the protein's dual potential as both a therapeutic target and a treatment agent. Thus, the study of recombinant VEGFC is an important facet of modern biomedical research, providing insights that could lead to novel strategies in treating diseases associated with vascular dysfunction.